Caribou Biosciences’ CEO on working toward a pivotal trial in 2nd line LBCL
Rachel Haurwitz describes recent data and the durability profile of Caribou’s allogeneic CAR-T product as the company plans to discuss a pivotal trial design with FDA.
Also look for unique social pages for BiotechTV U.
#1. Pfizer’s CEO on Q2 earnings.
#2. Moderna CEO Stéphane Bancel on Moderna’s business at its R&D Day in New York
#3. UPenn’s Bruce Levine discusses the progress of CAR-T
#4. Learning about gene writing at Tessera Therapeutics
#5. Visiting Bayer’s Research and Innovation Center in Kendall Square